Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.

Pediatric blood & cancer - 1 Sept 2024

Chang Ya-Hsuan, Yu Chih-Hsiang, Lu Meng-Yao, Jou Shiann-Tarng, Lin Chien-Yu, Lin Kai-Hsin, Chang Hsiu-Hao, Ni Yu-Ling, Chou Shu-Wei, Ko Kuan-Yin, Lin Dong-Tsamn, Hsu Wen-Ming, Chen Hsuan-Yu, Yang Yung-Li

Abstract excerpt

INTRODUCTION: Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. Our aim was to identify prognostic genetic markers for patients with neuroblastoma, who were treated with the Taiwan Pediatric Oncology Group (TPOG) neuroblastoma N2002 protocol, to improve risk stratification and inform treatment. METHODS: Our analysis was based on 53 primary neuroblastoma specimens, diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Follow-Up Studies

Share to Neuroblastoma

Share to Prognosis

Share to Survival Rate

Share to Tumor Burden

Source

Identifiers

PMID: 38967585
DOI: 10.1002/pbc.31176

Genes

ALK
MYCN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.PMID 38967585Read ↗

Clinical Impact of Tumor Mutational Burden in NeuroblastomaSemantic proximity Read ↗

Molecular targeting therapies for neuroblastoma: Progress and challengesSemantic proximity Read ↗

Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.Semantic proximity Read ↗

Molecular Basis and Clinical Features of NeuroblastomaSemantic proximity Read ↗

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapySemantic proximity Read ↗

Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors.Semantic proximity Read ↗

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterationsSemantic proximity Read ↗

Research progress of neuroblastoma related gene variations.Semantic proximity Read ↗

Genetics and genomics of neuroblastoma.Semantic proximity Read ↗

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.Semantic proximity Read ↗

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Genetic discoveries and treatment advances in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.